Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118151991> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W3118151991 endingPage "912" @default.
- W3118151991 startingPage "901" @default.
- W3118151991 abstract "Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine involved in asthma pathogenesis. In the phase 2b PATHWAY study (ClinicalTrials.gov identifier: NCT02054130), tezepelumab significantly reduced exacerbations in adults with severe, uncontrolled asthma. We used pharmacokinetic (PK) and pharmacodynamic (PD) modeling to guide tezepelumab dose selection for phase 3 trials in patients with severe asthma. PK data from 7 clinical studies were used to develop a population PK model. Population PK-PD models were developed to characterize the relationship between tezepelumab PK and asthma exacerbation rate (AER) and fractional exhaled nitric oxide (FeNO) levels (using phase 2b PD data only). Tezepelumab PK were well described by a 2-compartment model with first-order absorption; PK parameter estimates were consistent with those of other immunoglobulin G2 antibodies. PK-PD models predicted that subcutaneous dosing at 210 mg every 4 weeks was associated with ≈90% of the maximum drug effect of tezepelumab on AER and FeNO; further dose increases were not expected to result in additional, clinically meaningful treatment benefit. No clinically significant covariates of treatment effects on AER and FeNO were identified. Population PK simulations, exposure-response relationships and safety profiles of tezepelumab at doses up to 280 mg every 2 weeks suggested that no dose adjustment based on body weight or for adolescents was required. These results support the selection of 210 mg every 4 weeks subcutaneously as the dose for phase 3 studies of tezepelumab in adults and adolescents with severe asthma." @default.
- W3118151991 created "2021-01-05" @default.
- W3118151991 creator A5016643106 @default.
- W3118151991 creator A5030343988 @default.
- W3118151991 creator A5036942082 @default.
- W3118151991 creator A5044514961 @default.
- W3118151991 creator A5044664487 @default.
- W3118151991 creator A5067601115 @default.
- W3118151991 creator A5069627913 @default.
- W3118151991 date "2021-01-16" @default.
- W3118151991 modified "2023-10-18" @default.
- W3118151991 title "Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma" @default.
- W3118151991 cites W146790210 @default.
- W3118151991 cites W1975438745 @default.
- W3118151991 cites W2015186160 @default.
- W3118151991 cites W2055172715 @default.
- W3118151991 cites W2067933166 @default.
- W3118151991 cites W2162803006 @default.
- W3118151991 cites W2752584372 @default.
- W3118151991 cites W2904772462 @default.
- W3118151991 cites W2910199101 @default.
- W3118151991 cites W2916779934 @default.
- W3118151991 cites W3002655771 @default.
- W3118151991 doi "https://doi.org/10.1002/jcph.1803" @default.
- W3118151991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33368307" @default.
- W3118151991 hasPublicationYear "2021" @default.
- W3118151991 type Work @default.
- W3118151991 sameAs 3118151991 @default.
- W3118151991 citedByCount "7" @default.
- W3118151991 countsByYear W31181519912021 @default.
- W3118151991 countsByYear W31181519912022 @default.
- W3118151991 countsByYear W31181519912023 @default.
- W3118151991 crossrefType "journal-article" @default.
- W3118151991 hasAuthorship W3118151991A5016643106 @default.
- W3118151991 hasAuthorship W3118151991A5030343988 @default.
- W3118151991 hasAuthorship W3118151991A5036942082 @default.
- W3118151991 hasAuthorship W3118151991A5044514961 @default.
- W3118151991 hasAuthorship W3118151991A5044664487 @default.
- W3118151991 hasAuthorship W3118151991A5067601115 @default.
- W3118151991 hasAuthorship W3118151991A5069627913 @default.
- W3118151991 hasConcept C111113717 @default.
- W3118151991 hasConcept C112705442 @default.
- W3118151991 hasConcept C126322002 @default.
- W3118151991 hasConcept C2776042228 @default.
- W3118151991 hasConcept C2776239304 @default.
- W3118151991 hasConcept C2777014857 @default.
- W3118151991 hasConcept C2777288759 @default.
- W3118151991 hasConcept C2778070265 @default.
- W3118151991 hasConcept C2780333948 @default.
- W3118151991 hasConcept C2781142857 @default.
- W3118151991 hasConcept C2908647359 @default.
- W3118151991 hasConcept C71924100 @default.
- W3118151991 hasConcept C98274493 @default.
- W3118151991 hasConcept C99454951 @default.
- W3118151991 hasConceptScore W3118151991C111113717 @default.
- W3118151991 hasConceptScore W3118151991C112705442 @default.
- W3118151991 hasConceptScore W3118151991C126322002 @default.
- W3118151991 hasConceptScore W3118151991C2776042228 @default.
- W3118151991 hasConceptScore W3118151991C2776239304 @default.
- W3118151991 hasConceptScore W3118151991C2777014857 @default.
- W3118151991 hasConceptScore W3118151991C2777288759 @default.
- W3118151991 hasConceptScore W3118151991C2778070265 @default.
- W3118151991 hasConceptScore W3118151991C2780333948 @default.
- W3118151991 hasConceptScore W3118151991C2781142857 @default.
- W3118151991 hasConceptScore W3118151991C2908647359 @default.
- W3118151991 hasConceptScore W3118151991C71924100 @default.
- W3118151991 hasConceptScore W3118151991C98274493 @default.
- W3118151991 hasConceptScore W3118151991C99454951 @default.
- W3118151991 hasIssue "7" @default.
- W3118151991 hasLocation W31181519911 @default.
- W3118151991 hasLocation W31181519912 @default.
- W3118151991 hasOpenAccess W3118151991 @default.
- W3118151991 hasPrimaryLocation W31181519911 @default.
- W3118151991 hasRelatedWork W1969175189 @default.
- W3118151991 hasRelatedWork W2004325424 @default.
- W3118151991 hasRelatedWork W2021319218 @default.
- W3118151991 hasRelatedWork W2120222132 @default.
- W3118151991 hasRelatedWork W2227061539 @default.
- W3118151991 hasRelatedWork W2398694035 @default.
- W3118151991 hasRelatedWork W2615248318 @default.
- W3118151991 hasRelatedWork W3021369409 @default.
- W3118151991 hasRelatedWork W3174177415 @default.
- W3118151991 hasRelatedWork W4284884935 @default.
- W3118151991 hasVolume "61" @default.
- W3118151991 isParatext "false" @default.
- W3118151991 isRetracted "false" @default.
- W3118151991 magId "3118151991" @default.
- W3118151991 workType "article" @default.